In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer Schering Pharma, Novartis in Betaseron deal

Executive Summary

After negotiating for several months, Bayer Schering Pharma has settled a contract manufacturing dispute and agreed to pay Novartis $110mm in cash to buy the Emeryville, California-based biologics facilities where Bayer's multiple sclerosis drug Betaseron (interferon beta-1b) is produced. The companies have also signed an alliance covering a new branded version of interferon beta-1b that Novartis will develop and market.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)
    • Product or Technology Swap

Related Companies